repaglinide has been researched along with ru 66647 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Backman, JT; Kajosaari, LI; Neuvonen, PJ; Niemi, M | 1 |
| Abernethy, DR; Arya, V; Atkinson, AJ; Berglund, EG; Grillo, JA; Huang, SM; Lesko, LJ; Pang, KS; Reynolds, KS; Song, P; Sugiyama, Y; Vieira, Mde L; Wu, TC; Zhang, L; Zhao, P; Zheng, JH | 1 |
1 trial(s) available for repaglinide and ru 66647
| Article | Year |
|---|---|
Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.
Topics: Acetates; Adolescent; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biotransformation; Blood Glucose; Carbamates; Cross-Over Studies; Cyclopropanes; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Hypoglycemic Agents; Ketolides; Leukotriene Antagonists; Male; Piperidines; Quinolines; Sulfides | 2006 |
1 other study(ies) available for repaglinide and ru 66647
| Article | Year |
|---|---|
Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation.
Topics: Area Under Curve; Carbamates; Chronic Disease; Computer Simulation; Drug Interactions; Humans; Ketolides; Kidney Diseases; Models, Biological; Piperazines; Piperidines; Purines; Sildenafil Citrate; Sulfones | 2012 |